Larimar Therapeutics Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +337.5% | +202.9% | -11.3% | +38.8% | -70.1% | +98.7% | +110.3% | -2.5% | -2.2% | +2.3% | +10.1% | |
| – | +452.6% | – | – | – | -25.4% | +1,575.2% | +153.3% | +20.9% | +15.0% | +15.5% | -20.4% | |
| – | – | – | – | – | -25.4% | +1,582.9% | +151.4% | +21.3% | – | – | – | |
| – | +725.6% | -181.7% | – | – | -61.9% | -1,004.0% | – | -39.2% | -250.4% | – | +662.7% | |
| – | +925.9% | +10.9% | -91.7% | +96.4% | -23.1% | -25.3% | +437.1% | -70.0% | +64.0% | +214.0% | -82.3% | |
| – | +60.7% | – | -30.7% | -119.3% | -98.8% | – | +41.4% | -476.3% | – | -356.0% | – | |
| – | – | -99.8% | -11.4% | +34,371.8% | -99.7% | +38,864.9% | – | – | – | – | – | |
| – | +19.4% | -102.1% | – | +304.0% | -71.0% | +382.5% | -78.8% | +278.5% | -100.0% | +539,510.0% | -59.8% | |
| – | -199.7% | – | – | +1.5% | -664.9% | – | -97.2% | -2,320.2% | – | – | +809.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.